terazosin has been researched along with Hyperlipemia in 2 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
| Excerpt | Relevance | Reference |
|---|---|---|
| " This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease." | 9.09 | [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| " This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease." | 5.09 | [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| " No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe." | 2.70 | [The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy]. ( Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tamaki, M | 1 |
| Ueda, T | 1 |
| Kageyama, S | 1 |
| Suzuki, Y | 1 |
| Katoh, T | 1 |
| Isurugi, K | 1 |
| Obara, W | 1 |
| Omori, S | 1 |
| Goto, Y | 1 |
| Fujioka, T | 1 |
| Numasato, S | 1 |
2 trials available for terazosin and Hyperlipemia
| Article | Year |
|---|---|
[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
Topics: Aged; Coronary Disease; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Prazosin; Prostatic Hype | 1999 |
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prazos | 2001 |